DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
Despite intensive therapy, children with high-risk neuroblastoma are at risk of treatment failure. We applied a multiomic system approach to evaluate metabolic vulnerabilities in human neuroblastoma. We combined metabolomics, CRISPR screening, and transcriptomic data across more than 700 solid tumor...
Main Authors: | Thale Kristin Olsen, Cecilia Dyberg, Bethel Tesfai Embaie, Adele Alchahin, Jelena Milosevic, Jane Ding, Jörg Otte, Conny Tümmler, Ida Hed Myrberg, Ellen M. Westerhout, Jan Koster, Rogier Versteeg, Han-Fei Ding, Per Kogner, John Inge Johnsen, David B. Sykes, Ninib Baryawno |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2022-10-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.153836 |
Similar Items
-
Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastoma
by: Thale K. Olsen, et al.
Published: (2024-08-01) -
DHODH modulates transcriptional elongation in the neural crest and melanoma
by: White, Richard Mark, et al.
Published: (2014) -
Research Progress on Mechanism of Action of DHODH in Progression of Malignant Tumors
by: CHE Xin, et al.
Published: (2024-03-01) -
The Warburg effect modulates DHODH role in ferroptosis: a review
by: Alvan Amos, et al.
Published: (2023-05-01) -
Cell state plasticity in neuroblastoma
by: Adam D. Durbin, et al.
Published: (2024-12-01)